NAII Continues To Seek Changes In Draft Privacy Reg. In Fla., Citing 'Overly Broad' Definition Of Consumer

September 2001
Insurance Advocate;9/15/2001, Vol. 112 Issue 35, p5
Reports on the changes proposed by the National Association of Independent Insurers to the draft privacy regulations in Florida as of September 2001. Concerns regarding the duplicative requirements for disclosure of non-public personal health information; Comment on the definition of consumers in the draft regulations; Effort to remove the health information privacy provisions in the regulation.


Related Articles

  • Medicine and the Media: Balancing the Public’s Right to Know With the Privacy of the Patient. Burkle, Christopher M.; Cascino, Gregory D. // Mayo Clinic Proceedings;Dec2011, Vol. 86 Issue 12, p1192 

    In this article the authors discuss the tort law and constitutional restrictions imposed on the disclosure of information related to health care to the public forum in the U.S. According to the authors, laws related to defamation and invasion of privacy help to balance an individual's right to...

  • Privacy of "insurer information"  // Canadian Underwriter;Jan2006, Vol. 73 Issue 1, p72 

    Discusses a ruling issued by Alberta Information and Privacy Commission adjudicator Dave Bell on the issue of insurer information as defined by the Canadian Insurance Act. Justification for the ruling; Primacy of the provisions of the Insurance Act with respect to insurer information.

  • Bush administration delays final HIPAA privacy rules. Elswick, Jill // Employee Benefit News;Apr2001, Vol. 15 Issue 4, p17 

    Looks at the provisions of the final privacy regulations under the Health and Information Portability and Accountability Act in the United States. Number of comments received for the proposed regulations; Disclosure requirements; Challenges posed for employers; Online resources available about...

  • Genetic Information: Consumers' Right to Privacy Versus Insurance Companies' Right to Know a Public Opinion Survey. Borna, Shaheen; Avila, Stephen // Journal of Business Ethics;May99 Part 1, Vol. 19 Issue 4, p355 

    In this paper we present arguments for and against the disclosure of genetic information to the insurance companies. One of the main issues which emerges from these arguments is the question of who should be responsible for the health insurance costs of the individuals who are most likely to be...

  • No place for secrecy.  // Money Marketing;3/13/2003, p33 

    Comments on the refusal of a British insurance firm to disclose information on the performance of its endowment policies. Reasons for the public's need to have access to investment information.

  • N.Y. Circular Letter Provides Guidance To Industry On Use Of CPAs In Consulting/Auditing.  // Insurance Advocate;3/11/2002, Vol. 113 Issue 10, p7 

    Reports the circular letter issued by the U.S. Department of Insurance to the insurance industry concerning the disclosure of consulting work performed by independent certified public accountants.

  • Insurance trade associations urge Texas Appeals Court to uphold data privacy decision.  // Insurance Advocate;12/19/98, Vol. 109 Issue 50, p22 

    Reports that the National Association of Independent Insurers (NAII) and other insurance companies have filed a brief with the Third Court of Appeals in Texas to uphold the Travis District Court's data privacy decision. Demand from former Department of Insurance official Birny Birnbaum for...

  • Survey Says.  // Marketing Health Services;Fall2004, Vol. 24 Issue 3, p4 

    The article reports the results of a survey of over 3500 U.S. adults asking personal health information, which respondents were not willing to share. Instead, respondents were willing to discuss gender and ethnic background. Willingness to share personal health information would have allowed...

  • German agency asks Pfizer to disclose all reboxetine data. Stafford, Ned // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/27/2009, Vol. 338 Issue 7710, p1522 

    The article focuses on a call from the Institute for Quality and Efficiency in Health Care based in Cologne, Germany for Pfizer to disclose all reboxetine data. The German agency has accused Pfizer of concealing research data on its depression treatment reboxetine. The public health insurance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics